<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Functional Dyspepsia – One‑Page Algorithm (NICE CKS May 2024)</title>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    :root{
      --bg:#f7f8fb;
      --card:#ffffff;
      --ink:#1f2937; /* slate-800 */
      --ink-muted:#4b5563; /* slate-600 */
      --brand:#2563eb; /* blue-600 */
      --accent:#0ea5e9; /* sky-500 */
      --ok:#16a34a; /* green-600 */
      --warn:#d97706; /* amber-600 */
      --danger:#dc2626; /* red-600 */
      --chip:#e0e7ff; /* indigo-100 */
      --shadow: 0 6px 20px rgba(31,41,55,.08);
      --radius: 18px;
    }
    html,body{height:100%}
    html{scroll-behavior:smooth}
    body{
      margin:0; font-family:Inter,system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial; color:var(--ink); background:var(--bg);
    }
    .container{max-width:1100px; margin-inline:auto; padding:28px;}
    header.hero{
      position:sticky; top:0; z-index:10; backdrop-filter:saturate(180%) blur(8px);
      background:linear-gradient(180deg, rgba(247,248,251,.9), rgba(247,248,251,.6));
      border-bottom:1px solid #e5e7eb;
    }
    .hero-inner{display:flex; align-items:center; justify-content:space-between; gap:16px; padding:18px 28px; max-width:1100px; margin:0 auto;}
    .title{
      display:flex; align-items:center; gap:14px;
    }
    .title h1{font-size:20px; font-weight:700; letter-spacing:.2px; margin:0}
    .badges{display:flex; gap:10px; flex-wrap:wrap}
    .chip{background:var(--chip); color:#3730a3; padding:6px 10px; border-radius:999px; font-weight:600; font-size:12px;}
    .cta{display:flex; gap:10px}
    button.btn{
      appearance:none; border:0; border-radius:12px; padding:10px 14px; font-weight:600; cursor:pointer; transition:transform .06s ease, box-shadow .2s ease; box-shadow:var(--shadow);
      background:var(--brand); color:#fff;
    }
    button.btn.secondary{background:#e5e7eb; color:#111827}
    button.btn:hover{transform:translateY(-1px)}

    /* layout */
    .grid{display:grid; grid-template-columns:1.2fr .8fr; gap:22px; margin-top:24px}
    @media (max-width: 980px){ .grid{grid-template-columns:1fr} }

    .card{background:var(--card); border-radius:var(--radius); box-shadow:var(--shadow); padding:22px}
    .card h2{margin:0 0 14px; font-size:18px}
    .sub{color:var(--ink-muted); font-size:13px}

    /* flow steps */
    .steps{display:flex; flex-direction:column; gap:14px}
    .step{background:#f9fafb; border:1px solid #eef2f7; border-radius:14px; padding:14px 16px; position:relative}
    .step .head{display:flex; align-items:center; gap:10px; margin-bottom:8px}
    .pill{font-size:11px; padding:4px 8px; border-radius:999px; font-weight:700; color:#fff;}
    .p-blue{background:var(--brand)}
    .p-green{background:var(--ok)}
    .p-amber{background:var(--warn)}
    .p-red{background:var(--danger)}
    .step ul{margin:6px 0 0 18px}
    .step li{margin:4px 0}

    /* columns in cards */
    .cols{display:grid; grid-template-columns:repeat(2, minmax(0,1fr)); gap:10px}
    @media (max-width: 640px){ .cols{grid-template-columns:1fr} }

    /* tables */
    table{width:100%; border-collapse:separate; border-spacing:0}
    th, td{padding:10px 12px; font-size:13px; text-align:left}
    thead th{background:#eef2ff; color:#1e3a8a; font-weight:700}
    tbody tr:nth-child(odd){background:#f8fafc}
    tbody tr:nth-child(even){background:#ffffff}
    tbody td{border-bottom:1px solid #eef2f7}

    .note{background:#fff7ed; color:#7c2d12; border:1px solid #fed7aa; border-radius:12px; padding:10px 12px; font-size:12px}

    /* footer */
    footer{color:#6b7280; font-size:12px; margin:18px auto 40px; text-align:center}

    /* print styles: one tidy page */
    @media print{
      header.hero{position:static; background:#fff; border:0}
      .cta{display:none}
      body{background:#fff}
      .container{padding:0}
      .grid{gap:14px}
      .card{box-shadow:none; padding:12px; page-break-inside:avoid}
      .note{page-break-inside:avoid}
    }
  </style>
</head>
<body>
  <header class="hero">
    <div class="hero-inner">
      <div class="title">
        <svg width="28" height="28" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
          <path d="M12 3c-4.97 0-9 4.03-9 9 0 3.87 2.35 7.16 5.69 8.49.41.08.56-.18.56-.39 0-.19-.01-.82-.01-1.49-2.06.38-2.6-.5-2.76-.96-.09-.23-.48-.96-.82-1.15-.28-.15-.68-.52-.01-.53.63-.01 1.08.58 1.23.82.72 1.21 1.87.87 2.33.66.07-.52.28-.87.51-1.07-1.83-.21-3.75-.92-3.75-4.07 0-.9.32-1.64.84-2.22-.08-.21-.36-1.07.08-2.22 0 0 .68-.22 2.24.85.65-.18 1.34-.27 2.03-.27.69 0 1.38.09 2.03.27 1.56-1.07 2.24-.85 2.24-.85.44 1.15.16 2.01.08 2.22.52.58.84 1.32.84 2.22 0 3.16-1.92 3.86-3.76 4.07.29.25.54.73.54 1.48 0 1.07-.01 1.93-.01 2.2 0 .21.15.47.56.39C18.65 19.16 21 15.87 21 12c0-4.97-4.03-9-9-9Z" fill="var(--brand)"/></svg>
        <h1>Functional Dyspepsia – One‑Page Algorithm</h1>
      </div>
      <div class="badges">
        <span class="chip">Adults ≥18y</span>
        <span class="chip">Primary Care</span>
        <span class="chip">NICE CKS (May 2024)</span>
      </div>
      <div class="cta">
        <button class="btn" onclick="window.print()">Print / Save PDF</button>
        <button class="btn secondary" onclick="window.location.hash='top'">Top</button>
      </div>
    </div>
  </header>

  <main class="container">
    <section class="grid">
      <article class="card" id="algorithm">
        <h2>Rapid Care Pathway</h2>
        <p class="sub">Use during consultations to streamline assessment, first‑line management, and escalation.</p>
        <div class="steps">
          <div class="step">
            <div class="head"><span class="pill p-red">Step 1</span><strong>Initial assessment</strong></div>
            <ul>
              <li><strong>Exclude alarm features</strong> → urgent referral if present (e.g., dysphagia, GI bleeding, unexplained weight loss, persistent vomiting, abdominal mass; age ≥55 with new onset + weight loss).</li>
              <li>Review medications that exacerbate symptoms (NSAIDs, steroids, bisphosphonates, CCBs, nitrates, theophyllines, TCAs, etc.).</li>
              <li>Lifestyle: weight loss, avoid triggers (coffee, chocolate, tomatoes, fatty/spicy foods), smaller meals; evening meal ≥3–4h before bed; stop smoking; reduce alcohol; manage stress.</li>
            </ul>
          </div>

          <div class="step">
            <div class="head"><span class="pill p-blue">Step 2</span><strong>Test &amp; treat for <em>H. pylori</em> (if status unknown)</strong></div>
            <ul>
              <li>Cease <strong>PPI ≥2 weeks</strong> and <strong>antibiotics ≥4 weeks</strong> before testing.</li>
              <li>Preferred test: <strong>13C‑urea breath test</strong>; alternative: stool antigen; locally validated serology if others unavailable.</li>
            </ul>
            <div class="cols">
              <div>
                <strong>If <em>H. pylori</em> positive → 7‑day eradication</strong>
                <ul>
                  <li><strong>PPI bid</strong> + <strong>Amoxicillin 1 g bid</strong> + <strong>Clarithromycin 500 mg bid</strong> <em>or</em> <strong>Metronidazole 400 mg bid</strong></li>
                  <li><u>Penicillin allergy</u>: PPI bid + Clarithromycin 500 mg bid + Metronidazole 400 mg bid</li>
                  <li><u>Pen allergy + prior clarithromycin</u>: <strong>Quadruple</strong> → PPI bid + Metronidazole 400 mg bid + Tetracycline 500 mg qid + Bismuth 525 mg qid</li>
                </ul>
              </div>
              <div>
                <strong>If <em>H. pylori</em> negative</strong>
                <ul>
                  <li>Trial: <strong>low‑dose PPI</strong> <em>or</em> <strong>standard‑dose H2RA</strong> for 1 month.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="step">
            <div class="head"><span class="pill p-amber">Step 3</span><strong>Refractory or recurrent symptoms</strong></div>
            <ul>
              <li>Re‑check for alarm features and alternative diagnoses (cardiac/hepatobiliary, etc.).</li>
              <li>Confirm adherence; reinforce lifestyle measures.</li>
              <li><strong>Re‑test <em>H. pylori</em> only if</strong>: poor compliance/timing; high local resistance; NSAID/aspirin indicated (esp. PUD history); family history of gastric cancer; severe or persistent symptoms; or patient request. Perform ≥4 weeks after therapy (<em>ideally</em> 8 weeks), off PPI ≥2 weeks and antibiotics ≥4 weeks.</li>
            </ul>
            <div class="cols">
              <div>
                <strong>If re‑test positive → 7‑day second‑line</strong>
                <ul>
                  <li>PPI bid + Amoxicillin 1 g bid + (Clarithromycin <em>or</em> Metronidazole not used first‑line)</li>
                  <li>If prior <em>clarithro + metro</em>: PPI bid + Amoxicillin 1 g bid + <u>Levofloxacin 250 mg bid*</u> <em>or</em> Tetracycline 500 mg qid</li>
                  <li><u>Pen allergy, no prior levo</u>: PPI bid + Metronidazole 400 mg bid + <u>Levofloxacin 250 mg bid*</u></li>
                  <li><u>Pen allergy + prior levo</u>: PPI bid + Bismuth 525 mg qid + Metronidazole 400 mg bid + Tetracycline 500 mg qid</li>
                </ul>
              </div>
              <div>
                <strong>If re‑test not indicated / negative</strong>
                <ul>
                  <li>Switch PPI ↔ H2RA; consider long‑term control at <em>lowest effective dose</em>.</li>
                  <li>Annual review; consider PRN PPI and short‑term antacid/alginate (avoid continuous long‑term use).</li>
                </ul>
              </div>
            </div>
            <p class="note"><strong>* Fluoroquinolones:</strong> prescribe only if commonly recommended alternatives are inappropriate (regulatory safety advice).</p>
          </div>

          <div class="step">
            <div class="head"><span class="pill p-green">Step 4</span><strong>Refer / specialist input</strong></div>
            <ul>
              <li>Refractory or recurrent symptoms despite optimal primary‑care management.</li>
              <li>Failed second‑line <em>H. pylori</em> eradication.</li>
              <li>Limited antibiotic options (hypersensitivity, resistance, multiple prior exposures).</li>
              <li>Possible investigations: barium swallow/meal; gastric scintigraphy (suspected delayed emptying); hydrogen breath tests (SIBO, lactose/fructose intolerance).</li>
              <li>Specialist therapies may include TCAs (for pain modulation/anxiety/depression) and adjunct probiotics (variable evidence).</li>
            </ul>
          </div>
        </div>
      </article>

      <aside class="card" id="quickrefs">
        <h2>Quick Reference</h2>
        <div class="step" style="margin-bottom:12px">
          <div class="head"><span class="pill p-blue">PPI Dosing (eradication)</span></div>
          <table aria-label="PPI dosing">
            <thead><tr><th>PPI</th><th>Dose (bid)</th></tr></thead>
            <tbody>
              <tr><td>Omeprazole</td><td>20–40 mg</td></tr>
              <tr><td>Lansoprazole</td><td>30 mg</td></tr>
              <tr><td>Pantoprazole</td><td>40 mg</td></tr>
              <tr><td>Rabeprazole</td><td>20 mg</td></tr>
              <tr><td>Esomeprazole</td><td>20 mg</td></tr>
            </tbody>
          </table>
        </div>

        <div class="step" style="margin-bottom:12px">
          <div class="head"><span class="pill p-green">Acid suppression trial</span></div>
          <ul>
            <li><strong>PPI (low dose)</strong> or <strong>H2RA (standard dose)</strong> × 1 month.</li>
            <li>Stop before endoscopy (≥2 weeks) to avoid masking pathology.</li>
          </ul>
        </div>

        <div class="step" style="margin-bottom:12px">
          <div class="head"><span class="pill p-amber">Long‑term management</span></div>
          <ul>
            <li>Consider lowest effective dose; PRN PPI where suitable.</li>
            <li>Annual medication + symptom review.</li>
          </ul>
        </div>

        <div class="step">
          <div class="head"><span class="pill p-red">Adjuncts</span></div>
          <ul>
            <li>Psychological therapies; relaxation strategies.</li>
            <li>Low‑dose TCAs for symptom modulation in selected patients.</li>
            <li>Probiotics as adjunct (evidence inconsistent).</li>
          </ul>
        </div>
      </aside>
    </section>

    <section class="card" id="safe-qs">
      <h2>Safety & Interactions (selected)</h2>
      <div class="cols">
        <div>
          <ul>
            <li><strong>PPIs</strong>: monitor for hypomagnesaemia in long‑term use; consider fracture risk in elderly/high‑dose/long‑term; avoid with clopidogrel (ome/esome preferred to avoid) by selecting alternative PPI where appropriate; stop ≥2 weeks pre‑endoscopy.</li>
            <li><strong>H2RAs</strong>: dose‑adjust in CKD; stop ≥2 weeks pre‑endoscopy.</li>
          </ul>
        </div>
        <div>
          <ul>
            <li><strong>Clarithromycin</strong>: numerous interactions (e.g., statins, warfarin, QT‑prolonging agents); avoid with ivabradine; use caution with edoxaban.</li>
            <li><strong>Amoxicillin</strong>: check true penicillin allergy; adjust in advanced CKD.</li>
          </ul>
        </div>
      </div>
      <p class="note"><strong>MHRA reminder:</strong> Systemic fluoroquinolones can cause serious, potentially long‑lasting adverse effects; reserve for when commonly recommended antibiotics are inappropriate.</p>
    </section>
  </main>

  <footer>
    Designed as a rapid aide‑mémoire for primary care. This summary is based on NICE CKS functional dyspepsia (May 2024). Always apply local antimicrobial guidance.
  </footer>
</body>
</html>